Kalvista Pharmaceuticals Inc (OQ:KALV)

Business Focus: Biopharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: Building 200, 1 Kendall Sq Ste 2203
CAMBRIDGE MA 02139-1562
Tel: N/A
Website: www.kalvista.com
IR: See website
Key People
Richard Aldrich
Chairman of the Board
Thomas Andrew Crockett
Chief Executive Officer, Director
Benjamin L. Palleiko
Chief Financial Officer
Christopher M Yea
Chief Development Officer
Business Overview
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Financial Overview
For the six months ended 31 October 2018, Kalvista Pharmaceuticals Inc revenues increased from $1.2M to $9.3M. Net loss decreased 16% to $8.3M. Revenues reflect Revenue increase from $1.1M to $9.3M. Lower net loss reflects Other income increase from $1.4M to $3.4M (income), Interest Income increase from $3K to $293K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.01 to -$0.68.
Employees: 14 as of Jan 9, 2015
Reporting Currency: U.S. Dollars
Enterprise value: $237.51M as of Oct 31, 2018
Annual revenue (TTM): $16.48M as of Oct 31, 2018
EBITDA (TTM): -$18.96M as of Oct 31, 2018
Net annual income (TTM): -$14.23M as of Oct 31, 2018
Free cash flow (TTM): $5.22M as of Oct 31, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 17,225,667 as of Dec 10, 2018
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization